^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Solid Tumor

    Related cancers:
    3ms
    UHFUS Characterization of Normal Lymphatic Anatomy (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, University of California, Davis
    New trial
    3ms
    PRIME-KS: Precision Imaging to Evaluate Kaposi Sarcoma (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    3ms
    NRG-CC009: Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability (clinicaltrials.gov)
    P3, N=200, Recruiting, NRG Oncology | Trial primary completion date: Jul 2028 --> Jun 2026
    Trial primary completion date
    3ms
    A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE) (clinicaltrials.gov)
    P=N/A, N=35, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    3ms
    Study on the Association Between Serrated Polyps and Metachronous Advanced Colorectal Neoplastic Lesions (clinicaltrials.gov)
    P=N/A, N=750, Not yet recruiting, Changhai Hospital
    New trial
    3ms
    Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (clinicaltrials.gov)
    P2, N=100, Recruiting, Jeeyun Lee | N=50 --> 100
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • CLDN18.2 positive
    |
    Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    3ms
    UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-3 (UNITED-3) (clinicaltrials.gov)
    P=N/A, N=70, Active, not recruiting, Sunnybrook Health Sciences Centre | Recruiting --> Active, not recruiting
    Enrollment closed
    3ms
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (clinicaltrials.gov)
    P2, N=2, Active, not recruiting, National Cancer Institute (NCI) | N=240 --> 2 | Trial completion date: Oct 2027 --> Jun 2027 | Trial primary completion date: Oct 2027 --> Jan 2026
    Enrollment change • Trial completion date • Trial primary completion date • MSI-H • dMMR
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    3ms
    TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=17, Completed, Mayo Clinic | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026
    Trial completion • Trial completion date
    |
    HER-2 negative • HER-2 expression
    |
    paclitaxel • fulvestrant • letrozole • Herzuma (trastuzumab-pkrb) • anastrozole • exemestane • Trazimera (trastuzumab-qyyp) • denifanstat (TVB-2640)
    3ms
    GPC3-Targeted PET/CT in Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, The First Affiliated Hospital of Xiamen University
    New trial
    3ms
    EPIK-RO: Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety. (clinicaltrials.gov)
    P2, N=51, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Piqray (alpelisib) • fulvestrant • letrozole
    3ms
    A Disposable Negative Pressure Wound Therapy Device (SNaP) to Promote Wound Healing in the Lower Limbs Following Mohs Micrographic Surgery for Non-melanoma Skin Cancer (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jun 2030 --> Dec 2030
    Trial primary completion date